Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) announced the successful completion of a 300-gram scale-up batch of A83B4C63, the active pharmaceutical ingredient for its proprietary ONC010 drug candidate. The batch, produced under Dalton Pharma Services' Process Optimization and Intermediate Scale-Up Program, achieved approximately 99.3% purity with no detectable residual solvents, according to a company press release.
The milestone marks a significant step forward for Onco-Innovations' PNKP inhibitor program, demonstrating the reproducibility and scalability of the manufacturing process. The company said the results are expected to support future analytical qualification, formulation development, engineering batch production and Good Manufacturing Practice (GMP) manufacturing activities ahead of planned First-in-Human studies.
"This scale-up campaign confirms that our manufacturing process is robust and scalable," the company stated, emphasizing the importance of the achievement for advancing ONC010 toward clinical development. The drug candidate targets solid tumors through a patented technology for which Onco-Innovations holds an exclusive worldwide license.
In addition to the manufacturing update, Onco-Innovations announced the appointment of Dave Antony as chief financial officer and corporate secretary, effective immediately. Antony succeeds Nico Mah. The company did not provide further details on the transition.
The announcement comes as Onco-Innovations continues to progress its oncology pipeline. The company, based in Canada, focuses on cancer research and treatment, specializing in innovative solutions for solid tumors. The successful scale-up batch is a critical prerequisite for regulatory filings and clinical trial initiation.
For more information, the full press release is available at https://ibn.fm/NJVb1. Updates on ONNVF are posted in the company's newsroom at https://ibn.fm/ONNVF.
The development underscores the progress being made in targeted cancer therapies, with Onco-Innovations positioning itself to potentially offer new treatment options for patients with solid tumors.
